CD8A and neoplasm: IL2-tethered small EVs (IL2-sEVs) derived from engineered Jurkat T cells have been shown to enhance CD8+ T cell anticancer activity and reduce PD-L1 expression in melanoma cells, thereby reshaping the immunosuppressive tumor microenvironment [212].